You are reading it right, but that’s the wrong chart. That chart is for symptomatic infection. Not really what you care most about.Am I reading it right that at 10 week the difference between double pfizer and pfizer boosted is 25%-45% against omicron? Moderna substantially better?
If so, the policy implication from this is they really shouldn't be boosting young men (the gain is negligible and both seem to decline with time, though we don't know what the floor is for the pfizer booster yet) and elderly and immunocompromised should only be getting boosted with moderna (if they go a 4th for this group, it would seem to need to Moderna). Also makes the FDA bypassing the expert panel on 12-15 year old boosters egregious.
The data for hospitalization is what you need.
Click on goalie’s link to UK data. https://assets.publishing.service.g...efing-31-Dec-2021-Omicron_severity_update.pdf
Page 12. It puts the booster at 88% effective against hospitalization.
“These estimates suggest that vaccine effectiveness against symptomatic disease with the Omicron variant is significantly lower than compared to the Delta variant and wanes rapidly. Nevertheless, protection against hospitalisation is much greater than that against symptomatic disease, in particular after a booster dose, where vaccine effectiveness against hospitalisation is close to 90%.”